WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ADAP

Based on 3 analysts offering 12 month price targets for Adaptimmune Therapeutics PLC

Min Forecast
$0.46+736.36%
Avg Forecast
$0.65+1,087.27%
Max Forecast
$1.00+1,718.18%

Should I buy or sell ADAP stock?

Based on 3 analysts offering ratings for Adaptimmune Therapeutics PLC.

Sell
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%

Be the first to know when Wall Street analysts revise their ADAP stock forecasts and price targets.

ADAP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-26
lockedlocked$00.00+00.00%2025-05-14
lockedlocked$00.00+00.00%2025-05-14

1 of 1

Forecast return on equity

Is ADAP forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ADAP forecast to generate an efficient return on assets?

Company
N/A
Industry
109.72%

ADAP earnings per share forecast

What is ADAP's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.43
Avg 2 year Forecast
-$0.26
Avg 3 year Forecast
-$0.46

ADAP revenue forecast

What is ADAP's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$33.9M-47.97%
Avg 2 year Forecast
$42.2M-35.12%
Avg 3 year Forecast
$118.8M+82.47%
ADAP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADAP revenue growth forecast

How is ADAP forecast to perform vs Biotechnology companies and vs the US market?

Company
17.6%
Industry
108.79%
Market
25.21%
ADAP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADAP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADAP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADAP$0.06$0.65+1,087.27%Sell
GOVX$0.57$9.00+1,470.68%Strong Buy
THAR$3.09N/AN/A
BIVI$1.89N/AN/A
MBRX$0.50$4.00+706.45%Buy
View Top Biotech Stocks

Adaptimmune Therapeutics Stock Forecast FAQ

Is Adaptimmune Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: ADAP) stock is to Sell ADAP stock.

Out of 3 analysts, 0 (0%) are recommending ADAP as a Strong Buy, 0 (0%) are recommending ADAP as a Buy, 2 (66.67%) are recommending ADAP as a Hold, 0 (0%) are recommending ADAP as a Sell, and 1 (33.33%) are recommending ADAP as a Strong Sell.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.

What is ADAP's earnings growth forecast for 2025-2027?

(NASDAQ: ADAP) Adaptimmune Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.04%.

Adaptimmune Therapeutics's earnings in 2025 is -$169,756,000.On average, 7 Wall Street analysts forecast ADAP's earnings for 2025 to be -$681,288,610, with the lowest ADAP earnings forecast at -$732,496,577, and the highest ADAP earnings forecast at -$617,835,259. On average, 7 Wall Street analysts forecast ADAP's earnings for 2026 to be -$413,639,513, with the lowest ADAP earnings forecast at -$779,251,678, and the highest ADAP earnings forecast at -$16,698,250.

In 2027, ADAP is forecast to generate -$729,952,082 in earnings, with the lowest earnings forecast at -$701,326,510 and the highest earnings forecast at -$751,421,260.

What is ADAP's revenue growth forecast for 2025-2027?

(NASDAQ: ADAP) Adaptimmune Therapeutics's forecast annual revenue growth rate of 17.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.21%.

Adaptimmune Therapeutics's revenue in 2025 is $65,085,000.On average, 7 Wall Street analysts forecast ADAP's revenue for 2025 to be $53,854,242,466, with the lowest ADAP revenue forecast at $40,521,087,232, and the highest ADAP revenue forecast at $67,460,930,941. On average, 7 Wall Street analysts forecast ADAP's revenue for 2026 to be $67,155,591,508, with the lowest ADAP revenue forecast at $64,522,038,900, and the highest ADAP revenue forecast at $69,130,755,965.

In 2027, ADAP is forecast to generate $188,865,161,683 in revenue, with the lowest revenue forecast at $181,454,319,199 and the highest revenue forecast at $194,415,341,999.

What is ADAP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ADAP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 109.72%.

What is ADAP's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ADAP price target, the average ADAP price target is $0.65, with the highest ADAP stock price forecast at $1.00 and the lowest ADAP stock price forecast at $0.46.

On average, Wall Street analysts predict that Adaptimmune Therapeutics's share price could reach $0.65 by Jun 26, 2026. The average Adaptimmune Therapeutics stock price prediction forecasts a potential upside of 1,087.27% from the current ADAP share price of $0.06.

What is ADAP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ADAP) Adaptimmune Therapeutics's current Earnings Per Share (EPS) is -$0.66. On average, analysts forecast that ADAP's EPS will be -$0.43 for 2025, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.39. On average, analysts forecast that ADAP's EPS will be -$0.26 for 2026, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.01. In 2027, ADAP's EPS is forecast to hit -$0.46 (min: -$0.44, max: -$0.47).

What is ADAP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ADAP) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.